Comprehensive Product Description Guide: Coversyl Plus HD

Coversyl Plus HD is a triple-combination antihypertensive containing Perindopril, Indapamide, and Amlodipine. It is prescribed for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled by dual therapy, providing 24-hour blood pressure regulation and cardiovascular protection.

Coversyl Plus HD Tablets
(Perindopril arginine + Indapamide + Amlodipine)

Perindopril Arginine – ACE Inhibitor

Indapamide – Thiazide-like Diuretic

Amlodipine Besylate – Calcium Channel Blocker

Perindopril Triple Combination Tablets

Generic Coversyl Plus HD

Triple Combination Antihypertensive

Perindopril + Indapamide + Amlodipine

Therapeutic Class: Antihypertensive Agent

Pharmacological Classes:

ACE Inhibitor (Perindopril)

Thiazide-like Diuretic (Indapamide)

Dihydropyridine Calcium Channel Blocker (Amlodipine)

Schedule: S4 (Prescription Medicine in Australia)

Coversyl Plus HD delivers a synergistic effect by targeting three distinct mechanisms:

Perindopril reduces angiotensin II production, leading to vasodilation, reduced aldosterone secretion, and improved arterial compliance.

Indapamide increases renal sodium and water excretion, reducing blood volume and peripheral resistance, thereby decreasing blood pressure.

Amlodipine inhibits calcium influx into vascular smooth muscle, resulting in arterial vasodilation and decreased systemic vascular resistance.

Together, this triple therapy ensures more effective and sustained blood pressure control and provides enhanced cardiovascular protection, especially for high-risk patients.

Treatment of essential hypertension in patients whose blood pressure is inadequately controlled by dual-component therapy

Management of high cardiovascular risk, such as patients with diabetes, chronic kidney disease, or prior stroke/MI

Used as a step-up therapy when lifestyle changes and monotherapy/dual therapy are insufficient

Form: Oral tablets (available in strengths such as 10mg/2.5mg/5mg)

Usual Adult Dose:

One tablet daily, preferably taken in the morning before a meal

Dose must be adjusted based on clinical response, kidney function, and previous therapy

Recommended Starting Dose (if switching from dual therapy):

5mg Perindopril + 1.25mg Indapamide + 5mg Amlodipine OR

10mg Perindopril + 2.5mg Indapamide + 5mg Amlodipine

Prescription Required: Yes

Manufacturer: Servier or equivalent generic brands

Pack Sizes: Typically 30 tablets

Route of Administration: Oral

Storage Conditions: Below 25°C, protect from moisture

Hypersensitivity to any component

History of angioedema related to ACE inhibitors

Severe hypotension, hypokalemia, hyponatremia

Severe renal or hepatic impairment

Pregnancy and lactation

Gout (due to diuretic component)

Warnings and Precautions:
Monitor serum electrolytes and renal function regularly

Use caution in elderly and volume-depleted patients

Risk of hypotension, particularly after first dose

May increase uric acid and glucose levels

Photosensitivity reactions (Indapamide-related)

Headache

Dizziness

Peripheral edema

Fatigue

Muscle cramps

Dry cough (Perindopril-related)

Gastrointestinal discomfort

Visual disturbances

Increased urination

Hypokalemia or hyponatremia

Palpitations

Angioedema

Severe hypotension

Electrolyte imbalance

Acute kidney injury

Stevens-Johnson syndrome (rare)

Potassium supplements or potassium-sparing diuretics (e.g., spironolactone): Increased hyperkalemia risk

NSAIDs: Reduced antihypertensive effect, renal function impairment

Lithium: Increased lithium toxicity

Diuretics: Can potentiate the first-dose hypotension of perindopril

Grapefruit juice: May increase amlodipine plasma concentrations

Alcohol: Increases risk of orthostatic hypotension

ASCOT Trial: Amlodipine-based regimens provided better outcomes in BP control and reduced stroke and heart attacks compared to atenolol-based therapy.

ADVANCE Trial: ACE inhibitor + diuretic combination reduced renal and cardiovascular complications in diabetics.

EUROPA Trial: Perindopril reduced cardiovascular mortality in high-risk patients.

Triple therapy shown to improve compliance, reduce pill burden, and lower 24-hour blood pressure more effectively than dual therapy alone (Meta-analysis, Hypertension Journal, 2019).

FAQs – Frequently Asked Questions
Q: What is the advantage of Coversyl Plus HD over separate medications?
A: It combines three proven antihypertensive classes into a single daily tablet, improving convenience, adherence, and blood pressure control while reducing pill burden.

Q: Is Coversyl Plus HD suitable for diabetics?
A: Yes, with caution. It offers protective renal and cardiovascular effects in diabetics but requires regular electrolyte and renal function monitoring.

Q: How long does it take to show effect?
A: Blood pressure reduction may be observed within 1–2 weeks, with full effect typically within 4–6 weeks.

Q: Can I take this if I am already on two BP medicines?
A: Yes. Coversyl Plus HD is indicated for patients inadequately controlled on dual therapy. Consult your doctor for a supervised switch.

Q: What if I experience dizziness after the first dose?
A: This is often due to the initial drop in blood pressure. Sit or lie down until symptoms resolve. Contact your doctor if persistent.

Buy Coversyl Plus HD online Australia

Perindopril Amlodipine Indapamide tablets

Triple combination BP medicine

Prescription hypertension medicine

Best blood pressure tablets

ACE inhibitor + diuretic + calcium blocker

High BP treatment medication

Coversyl Plus HD generic

Cardiovascular risk reduction therapy

Buy antihypertensive tablets EZ Chemist